Stocks in play: Medicenna Therapeutics Corp
Today announced a grant of five patents covering the Company’s IL-2 and IL-4 Superkine platforms. These patents strengthen Medicenna’s intellectual property (IP) position across key markets and further support the Company’s lead clinical and preclinical programs. Medicenna Therapeutics Corp shares T.MDNA are trading up $0.02 at $0.88.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.